David M. Rubenstein
CIK: 0001543895
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (13 total)
- Sep 11, 2026CG
Carlyle Group Inc.
Gift(G)Direct100K shares- - Sep 11, 2026CG
Carlyle Group Inc.
Sale(S)Direct400K shares at avg. $42.74$17.1M - May 6, 2026MRNA
Moderna, Inc.
Award(A)DirectRestricted Stock Units
2.1K shares- - May 6, 2026MRNA
Moderna, Inc.
Award(A)DirectStock Option (Right to Buy)
9.7K shares- - Apr 30, 2026MRNA
Moderna, Inc.
Exercise(M)Direct8.1K shares- - Mar 19, 2026CG
Carlyle Group Inc.
Gift(G)Direct100K shares- - Mar 19, 2026CG
Carlyle Group Inc.
Sale(S)Direct500K shares at avg. $46.68$23.3M - Dec 10, 2025CG
Carlyle Group Inc.
Sale(S)Direct625K shares at avg. $56.55$35.3M - Dec 10, 2025CG
Carlyle Group Inc.
Gift(G)Direct625K shares- - Aug 5, 2025MRNA
Moderna, Inc.
Exercise(M)Direct850 shares- - Apr 30, 2025MRNA
Moderna, Inc.
Award(A)DirectStock Option (Right to Buy)
12.8K shares- - Apr 30, 2025MRNA
Moderna, Inc.
Award(A)DirectRestricted Stock Units
8.1K shares- - Apr 30, 2025MRNA
Moderna, Inc.
Exercise(M)Direct677 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 11, 2026 |  CG Carlyle Group Inc. | Gift(G) | 100,000 | - | $0 | Direct |
| Sep 11, 2026 | CG Carlyle Group Inc. | Sale(S) | 400,000 | $42.74 | $17,096,000 | Direct |
| May 6, 2026 |  MRNA Moderna, Inc. | Award(A) Restricted Stock Units | 2,092 | - | - | Direct |
| May 6, 2026 | MRNA Moderna, Inc. | Award(A) Stock Option (Right to Buy) | 9,681 | - | - | Direct |
| Apr 30, 2026 | MRNA Moderna, Inc. | Exercise(M) | 8,116 | - | $0 | Direct |
| Mar 19, 2026 | CG Carlyle Group Inc. | Gift(G) | 100,000 | - | $0 | Direct |
| Mar 19, 2026 | CG Carlyle Group Inc. | Sale(S) | 500,000 | $46.68 | $23,340,000 | Direct |
| Dec 10, 2025 | CG Carlyle Group Inc. | Sale(S) | 625,000 | $56.55 | $35,343,750 | Direct |
| Dec 10, 2025 | CG Carlyle Group Inc. | Gift(G) | 625,000 | - | - | Direct |
| Aug 5, 2025 | MRNA Moderna, Inc. | Exercise(M) | 850 | - | - | Direct |
| Apr 30, 2025 | MRNA Moderna, Inc. | Award(A) Stock Option (Right to Buy) | 12,756 | - | - | Direct |
| Apr 30, 2025 | MRNA Moderna, Inc. | Award(A) Restricted Stock Units | 8,116 | - | - | Direct |
| Apr 30, 2025 | MRNA Moderna, Inc. | Exercise(M) | 677 | - | - | Direct |
1-13 of 13 transactions
About Rubenstein David M.
Rubenstein David M. (SEC CIK 0001543895) files insider reports with the SEC as Director of Carlyle Group Inc. (CG) and Director of Moderna, Inc. (MRNA).
Signal8 holds 7 ownership filings by Rubenstein David M., all Form 4s, filed between May 1, 2025 and Sep 11, 2026. Those filings report 13 transactions, from Apr 30, 2025 to Sep 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Rubenstein David M.'s filings is in WASHINGTON, DC.
Recent filings by Rubenstein David M.
- Sep 11, 2026: Gift of CG shares (Form 4, code G).
- Sep 11, 2026: Open-market sale of CG shares (Form 4, code S).
- May 6, 2026: Grants or awards of MRNA derivative securities (2 lines, Form 4, code A).
- Apr 30, 2026: Option exercise of MRNA shares (Form 4, code M).
- Mar 19, 2026: Gift of CG shares (Form 4, code G).
Other insiders filing for Carlyle Group Inc. (CG)
- Nedelman Jeffrey, Co-President
- Heinzelman Kate Elizabeth, General Counsel
- Andrews Charles Elliott Jr., Chief Accounting Officer
- Plouffe Justin, Chief Financial Officer
- Redett John C., Co-President
- SCHWARTZ HARVEY M, Chief Executive Officer